Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Subscribe

Sci. Signal., 12 April 2011
Vol. 4, Issue 168, p. pe19
[DOI: 10.1126/scisignal.2001991]

PERSPECTIVES

Estrogen Receptor β: Switching to a New Partner and Escaping from Estrogen

Yuet-Kin Leung1,2,3 and Shuk-Mei Ho1,2,3*

1 Division of Environmental Genetics and Molecular Toxicology, Department of Environmental Health, University of Cincinnati Medical Center, Kettering Complex, Room 128, 3223 Eden Avenue, P.O. Box 670056, Cincinnati, OH 45267, USA.
2 Center of Environmental Genetics, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA.
3 Cincinnati Cancer Center, College of Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45267, USA.

Abstract: Estrogen receptor (ER) β, the "second" ER, plays a gatekeeper role by inhibiting cell proliferation, promoting apoptosis, and impeding the progression of prostate cancer. Ironically, its presumed ligand, 17β-estradiol, promotes cancer development in experimental models. The mechanisms underlying the interplay between estrogens and ERβ in prostate cancer remain largely unclear. Research on a previously unknown tethering partner of ERβ, Krüppel-like zinc finger transcription factor 5 (KLF5), and its downstream gene target (FOXO1) helps to unlock this puzzle. 17β-Estradiol is not required to maintain the tumor-suppressive function of ERβ in the prostate, a tissue with limited estrogen availability; moreover, the presence of 17β-estradiol abrogates ERβ- and KLF5-mediated signaling and promotes cellular proliferation. Future research into ERβ will likely involve this estrogen independency and the preference for binding nonclassical DNA elements through tethering. The development of ERβ-based therapies may lead to improved drug efficacy.

* Corresponding author. E-mail, shuk-mei.ho{at}uc.edu

Citation: Y.-K. Leung, S.-M. Ho, Estrogen Receptor β: Switching to a New Partner and Escaping from Estrogen. Sci. Signal. 4, pe19 (2011).

Read the Full Text


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Post-transcriptional Regulation of Human Breast Cancer Cell Proteome by Unliganded Estrogen Receptor {beta} via microRNAs.
G. Nassa, R. Tarallo, G. Giurato, M. R. De Filippo, M. Ravo, F. Rizzo, C. Stellato, C. Ambrosino, M. Baumann, N. Lietzen, et al. (2014)
Mol. Cell. Proteomics 13, 1076-1090
   Abstract »    Full Text »    PDF »
Erb-041, an Estrogen Receptor-{beta} Agonist, Inhibits Skin Photocarcinogenesis in SKH-1 Hairless Mice by Downregulating the WNT Signaling Pathway.
S. C. Chaudhary, T. Singh, S. S. Talwelkar, R. K. Srivastava, A. Arumugam, Z. Weng, C. A. Elmets, F. Afaq, L. Kopelovich, and M. Athar (2014)
Cancer Prevention Research 7, 186-198
   Abstract »    Full Text »    PDF »
High circulating estrogens and selective expression of ER{beta} in prostate tumors of Americans: implications for racial disparity of prostate cancer.
Z. Y. Abd Elmageed, K. Moroz, S. K. Srivastav, Z. Fang, B. E. Crawford, K. Moparty, R. Thomas, and A. B. Abdel-Mageed (2013)
Carcinogenesis 34, 2017-2023
   Abstract »    Full Text »    PDF »

To Advertise     Find Products


Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882